Clear Scientific Reports Positive Phase 2 Results for CS-1103, the First Investigational Therapeutic That Removes Fentanyl from the Body

Phase 2positiveCS-1103Positive

AI Analysis

Summary

Clear Scientific announced positive Phase 2 results for CS-1103, a small-molecule sequestrant that binds and inactivates fentanyl, with all trial endpoints met. Phase 3 is planned for H1 2027.

Clinical Trial Data

Phase

Phase 2

Primary Endpoint

Met

Outcome Details

Phase 2 trial met all endpoints

Importance:7/10

Sentiment:

0.85

Phase 2 resultspositive datafentanylsequestrantPhase 3 planned

Related Companies

$TRAX

Read the original article

Published by PR Newswire Biotech on October 1, 2026 3:09 PM

Read Original